Thr699
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr699  -  HER4 (human)

Site Information
TELVEPLtPSGTAPN   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 9430151

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 1 ) , mass spectrometry ( 2 , 3 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
breast cancer ( 3 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 ) , breast ( 2 , 3 )

Upstream Regulation
Putative in vivo kinases:
ERK1 (human) ( 1 )
Treatments:
phorbol_ester ( 1 ) , Trametinib ( 1 )

Downstream Regulation
Effects of modification on HER4:
enzymatic activity, inhibited ( 1 ) , phosphorylation ( 1 )
Effects of modification on biological processes:
signaling pathway regulation ( 1 )

References 

1

Haryuni RD, et al. (2019) Negative feedback regulation of ErbB4 tyrosine kinase activity by ERK-mediated non-canonical phosphorylation. Biochem Biophys Res Commun 514, 456-461
31053301   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info